Latest Share Chat

REMOVE ADS

Ampeak Energy Share News (AMP)

Ampeak Energy Information

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes

Get Live Data

2.70 0.00 (0.00%)

Bid:

2.60

Ask:

2.80

Spread: 0.20 (7.692%)

Market Cap: £19.52m

Last checked at -

Intraday Ampeak Energy Share Chart

REMOVE ADS

Ampeak Energy News

Amphion Innovations To Work With Debt Providers To Refinance Facility

(Alliance News) - Amphion Innovations PLC said Wednesday its debt providers have told the company the excess value of the collateral does not meet the...

Amphion Innovations Pledges Polarean Shares As Extra Security For Loan (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC said Monday it has pledged its holding in Polarean Imaging PLC as additional security against its loa...

Amphion Innovations Sells More Shares In Motif Bio As Loan Repayment (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC on Tuesday said it sold 3.3 million shares in its Motif Bio PLC partner company as a partial loan rep...

Amphion Innovations sells 1.8m shares in Motif Bio

(Sharecast News) - Medical technology business developer Amphion Innovations announced on Friday that 1,825,000 shares in its partner company, Motif B...

Amphion Innovations Sells Partner's Motif Bio Shares In Loan Repayment (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC on Friday said it sold 1.8 million shares in partner pharmaceutical company Motif Bio PLC to repay a ...

Amphion Innovations Agrees To Amend 2014 Loan Facility (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC said Monday it has amended its loan facility first agreed in 2014 and then amended last October.Amphi...

Amphion Innovations Extends Promissory Notes Due Date To End Of 2019 (ALLISS)

LONDON (Alliance News) - Amphion Innovations PLC said Tuesday it has amended the terms of its convertible promissory notes by extending the date which...

Motif Bio crashes as FDA calls for more data

(Sharecast News) - Motif Bio said it will need to raise new funds after the application for its skin infections treatment, iclaprim, was refused by th...